2238 Grosso, Dolores - Thomas Jefferson University - Thomas Jefferson University
Dr. Grosso

Dolores Grosso, DNP, CRNP

Contact Dr. Grosso

834 Chestnut Street
Suite 315
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
  2. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation
  3. Recent advances in haploidentical stem cell transplantation
  4. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML
  5. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
  6. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
  7. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  8. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  9. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  10. Cytoprotection in acute myelogenous leukemia (AML) therapy
  11. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  12. Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
  13. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  14. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  15. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  16. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
0